R. Wendel Naumann, MD

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses improving outcomes with chemotherapy for the neoadjuvant treatment of patients with ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.